¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"lymphocyte interaction"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
antigen-antibody interaction
Ç׿øÇ×ü»óÈ£ÀÛ¿ë
additive interaction
»ó°¡ÀÛ¿ë
binocular interaction
µÎ´«»óÈ£ÀÛ¿ë, ¾ç¾È»óÈ£ÀÛ¿ë
cell interaction
¼¼Æ÷»óÈ£ÀÛ¿ë
drug interaction
¾à¹°»óÈ£ÀÛ¿ë
dipolar interaction
½Ö±ØÀÚ»óÈ£ÀÛ¿ë
genetic interaction
À¯Àü»óÈ£ÀÛ¿ë
infant-mother interaction
¿µ¾Æ¾ö¸¶»óÈ£ÀÛ¿ë
interaction
»óÈ£ÀÛ¿ë
orbit interaction
±Ëµµ»óÈ£ÀÛ¿ë
primary interaction
ÀÏÂ÷»óÈ£ÀÛ¿ë
receptor-ligand interaction
¼ö¿ëü¸®°£µå»óÈ£ÀÛ¿ë
radiation interaction
¹æ»ç¼±»óÈ£ÀÛ¿ë
simple interaction
´Ü¼ø»óÈ£ÀÛ¿ë
atypical lymphocyte
ºñÁ¤Çü¸²ÇÁ±¸
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
3
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
interaction
»óÈ£ÀÛ¿ë
mixed lymphocyte culture
È¥ÇÕ¸²ÇÁ±¸¹è¾ç
lymphocyte
¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
additive interaction
»ó°¡ÀÛ¿ë
antigen-antibody interaction
Ç׿øÇ×ü¹ÝÀÀ
binocular interaction
¾ç¾È»óÈ£ÀÛ¿ë, µÎ´«»óÈ£ÀÛ¿ë
cell interaction
¼¼Æ÷»óÈ£ÀÛ¿ë
dipolar interaction
½Ö±ØÀÚ»óÈ£ÀÛ¿ë
drug interaction
¾à¹°»óÈ£ÀÛ¿ë
genetic interaction
À¯Àü»óÈ£ÀÛ¿ë
interaction
»óÈ£ÀÛ¿ë
infant-mother interaction
¿µ¾Æ¾ö¸¶»óÈ£ÀÛ¿ë
orbit interaction
±Ëµµ»óÈ£ÀÛ¿ë
primary interaction
ÀÏÂ÷»óÈ£ÀÛ¿ë
radiation interaction
¹æ»ç¼±»óÈ£ÀÛ¿ë
receptor-ligand interaction
¼ö¿ëü¹èÀ§ÀÚ»óÈ£ÀÛ¿ë
simple interaction
´Ü¼ø»óÈ£ÀÛ¿ë
tissue interaction
Á¶Á÷»óÈ£ÀÛ¿ë
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
T cell ; T lymphocyte ; thymus derived lymphocyte
T¼¼Æ÷ ; T¸²ÇÁ? ; Èä¼±À¯·¡¸²ÇÁ?
B cell/lymphocyte
B ¼¼Æ÷/¸²ÇÁ±¸
B lymphocyte
B ¸²ÇÁ±¸
B-lymphocyte
B ¸²ÇÁ±¸.
Bare lymphocyte syndrome
¹«Ç¥Áö¸²ÇÁ±¸ÁõÈıº
T cell/lymphocyte
T ¼¼Æ÷/¸²ÇÁ±¸
T lymphocyte
T ¸²ÇÁ±¸
T-lymphocyte
T-Àӯı¸
anti-lymphocyte globulin
¸²ÇÁ±¸ Çױ۷κҸ°
antigen, lymphocyte defined (LD)
¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
granulocyte-monocyte-lymphocyte antigens
°ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
granulocyte-platelet-lymphocyte antigens
°ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
hodgkins disease,lymphocyte predominance
¸²ÇÁ±¸ ÇöÀúÇü
primed lymphocyte
ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
primed lymphocyte typing
ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
1
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
lymphocyte interaction
¸²ÇÁ±¸»óÈ£ÀÛ¿ë.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
abnormality of cell interaction
¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
additive interaction
»ó°¡(ßÓÊ¥)ÀÛ¿ë.
antigen antibody interaction
Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
antigen antibody interaction
Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
antigen antibody interaction
Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
antigen-antibody interaction
Ç׿ø-Ç×ü»óÈ£ÀÛ¿ë
binocular interaction
¾ç¾È»óÈ£ÀÛ¿ë
cell interaction
¼¼Æ÷»óÈ£ÀÛ¿ë
cellular interaction
¼¼Æ÷»óÈ£ÀÛ¿ë
dipolar interaction
½Ö±ØÀÚ»óÈ£ÀÛ¿ë
dipole dipole interaction
½Ö±ØÀÚ ½Ö±ØÀÚ »óÈ£ÀÛ¿ë
drug interaction
¾à¹° »óÈ£ÀÛ¿ë
drug interaction
¾à¹°»óÈ£ÀÛ¿ë.
drug interaction
¾à¹°»óÈ£ÀÛ¿ë(å·ÚªßÓû»íÂéÄ).
drugs,interaction
»óÈ£ÀÛ¿ë(ßÓû»íÂéÄ)
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½